Target Price | $43.00 |
Price | $39.34 |
Potential |
9.30%
register free of charge
|
Number of Estimates | 6 |
6 Analysts have issued a price target TG Therapeutics, Inc. 2026 .
The average TG Therapeutics, Inc. target price is $43.00.
This is
9.30%
register free of charge
$55.00
39.81%
register free of charge
$11.00
72.04%
register free of charge
|
|
A rating was issued by 8 analysts: 7 Analysts recommend TG Therapeutics, Inc. to buy, 0 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the TG Therapeutics, Inc. stock has an average upside potential 2026 of
9.30%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 329.00 | 553.43 |
40.80% | 68.22% | |
EBITDA Margin | 12.83% | 35.78% |
42.35% | 178.88% | |
Net Margin | 7.11% | 27.27% |
18.37% | 283.81% |
6 Analysts have issued a sales forecast TG Therapeutics, Inc. 2025 . The average TG Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an TG Therapeutics, Inc. EBITDA forecast 2025. The average TG Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 TG Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average TG Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 0.15 | 0.97 |
66.67% | 546.67% | |
P/E | 40.62 | |
EV/Sales | 11.06 |
7 Analysts have issued a TG Therapeutics, Inc. forecast for earnings per share. The average TG Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
TG Therapeutics, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 04 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 15 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Nov 25 2024 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | Nov 05 2024 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 05 2024 |
TD Cowen |
Locked
➜
Locked
|
Locked | Oct 29 2024 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 18 2024 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 04 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 15 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Nov 25 2024 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
Nov 05 2024 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 05 2024 |
Locked
TD Cowen:
Locked
➜
Locked
|
Oct 29 2024 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 18 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.